VYNT: Cancer Gene Company is engaged in the development, commercialization and sales of molecular and biomarker based testing and services.
Internal purchase: 20/5, 4000 shares of the first innovation officer, with a price of USD 3.35. 24/5, 26/5 Chief Executive Officer 14500 shares, 21/5-24/5 Directors 30300 shares. Only insiders beat the market.$Vyant Bio, Inc.(VYNT)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments